All News
Do We Stop or Continue Treatment?
Remission had been a dream, an elusive concept. But then, with the introduction of biologics, conventional synthetic and targeted synthetic DMARDS, patients are able to live longer and with a better quality of life. While these therapeutics have been helpful, they are expensive and carry potential side effects. The big question looms: Do we stop or continue treatment?
Read Article
JAKi and TYK2i: What to use and when?
You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.
Read Article
Difficult toTreat PsA: Mainly Difficult to Define!
Dr. Aurelie Najm reports on abstract 0777 from the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/mqjhkfJ39B https://t.co/mdE8IrG27T
Dr. John Cush RheumNow ( View Tweet)
Watch: Ultrasound for PsA Stratification: Are We There Yet?
Dr. Aurelie Najm reports live from #ACR23
https://t.co/TeeBHl2LlU https://t.co/ObFtaJsTWp
Dr. John Cush RheumNow ( View Tweet)
The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease
#ACR23
The metabolomics facility was established recently at the @UHN @UofT @SchroederInst and we are already seeing the results. @KrembilF @CRASCRRheum @UofTRheum https://t.co/Azxq3k8w5g
Nigil Haroon MD, PhD, DM, FRCPC, FRCP, MBA NigilHaroon ( View Tweet)
Large French study on infection risk of PsA biologics
12k pts over 6 years
When compared to Humira, only Enbrel and Stelara had lower infection risk
Concurrent steroid use associated with increased infection 1.85HR
@RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
Robert B Chao, MD ( View Tweet)
Bastard et al. 12,071 French PsA. Low incidence serious infections on advanced therapy - 17 per 1,000 person-years. Significantly lower risk ETN (HR 0.70), UST (HR 0.56) vs ADA. Others similar. Abstr#2566 #ACR23 @RheumNow https://t.co/GGDvRxP9ht https://t.co/Ol7G1OG73t
Richard Conway ( View Tweet)
Do Probiotics Improve PsA?
Probiotics and gut microbiome is a hot topic in the research world and amongst patients. Often, one the questions I get after sharing the diagnosis of PsA is, “Is there anything I can eat/not eat to make this better?” #ACR23
https://t.co/aK56UXz3gs https://t.co/p2AuzcWyq9
Dr. John Cush RheumNow ( View Tweet)
In this Ph2b RCT of TAK-279 (TYK2i), pts w/ PsA given 15mg & 30mg achieved an ACR20 response at wk 12 vs. PBO(53.3% and 54.2% vs 29.2%, both p = 0.002)
⬆️common TEAEs: Npharyngitis, URTI, headache & rash
#ACR23 ABSL12 @RheumNow https://t.co/T6swJgw6vE
sheila ( View Tweet)
Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
Mithu Maheswaranathan, MD ( View Tweet)
Does clinical enthesitis correlate with ultrasound enthesitis in psoriatic pts?
52 wk study randomized to secukinumab or placebo found a long-term stable response of enthesitis control
BUT NO correlation between clinical & US enthesitis
@RheumNow #ACR23 Abs#2243 https://t.co/H7pESzYrNi
Robert B Chao, MD ( View Tweet)
Persistence of IL-17i vs. TNFi in PsA treatment
Large database study
Persistence of IL-17i slightly greater than TNFi over 12 months
Are IL-17i a better longterm strategy for PsA pts?
@RheumNow #ACR23 Abs# 2240 https://t.co/9km5XgXcLE
Robert B Chao, MD ( View Tweet)
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Janet Pope ( View Tweet)
Comorbidities, including heightened CV risk, are linked to severe psoriasis. However, understanding subclinical CV disease timing in psoriasis patients remains limited. Dr. Jack Cush at .@RheumNow explains why more research is needed in this area: https://t.co/3KqQavVEbP https://t.co/Xo8SH0RTh9
RWCS RWCSmtg ( View Tweet)
Retrospective database study from Japan of PsA pts:
At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx.
Dc rates lowest for risankizumab
🤔Reasons for switching/discontinuation not mentioned.
#ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE
sheila ( View Tweet)
Very cool meta analysis of IL17i RCTs in PsA
No change in MACE in DMARD naieve pts initiating IL17i across RCTs
A skosh underpowered but worthwhile question & useful data
@RheumNow #ACR23 Abstr2254 https://t.co/ZN8QYgSA1A
Mike Putman EBRheum ( View Tweet)
Another day, another bimekizumab (IL17i) study
Across 2 trials, improved PsA specific QOL ("PsAID") metrics
Nice to see focus on PROs & I always love a good spidergram
@RheumNow #ACR23 Absr2249 https://t.co/dsLXstPzt2
Mike Putman EBRheum ( View Tweet)
Always refreshing to hear from another specialist's point of view
Cardiologist @Bweber04 on CVD and rheumatologic diseases
Increased risk of death, MI and HF exacerbation in our pt population
Increased all cause mortality
@RheumNow #ACR23 https://t.co/yOkPOmxU4N
Robert B Chao, MD ( View Tweet)
Watch: Ultrasound for PsA Stratification: Are We There Yet?
Dr. Aurelie Najm reports live from #ACR23
https://t.co/TnDVbKXcd4 https://t.co/RTbjL2wbUj
Dr. John Cush RheumNow ( View Tweet)
